|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.2000 - 3.2000|
|52 Week Range||0.0500 - 100.0000|
|Beta (3Y Monthly)||0.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BIONIK Laboratories Corp. , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, yesterday announced financial results for its first quarter of fiscal year 2020, ended June 30, 2019.
BIONIK Laboratories Corp. , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, yesterday announced financial results for the fiscal year ended March 31, 2019.
Outcomes of trial, funded by The National Institute for Health Research Health Technology Assessment Program, presented at 5th European Stroke Organisation Conference
BIONIK Laboratories Corp. , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the third quarter of fiscal year 2019, ended December 31, 2018.
Company introduces new technology at the American Physical Therapy Association Combined Sections Meeting January 23-26 in Washington, D.C. The Company is showcasing the new technology for the first time at its booth (#736) at the American Physical Therapy Association Combined Sections Meeting (“APTA CSM”) being held January 23-26 at the Walter E. Washington Convention Center in Washington, D.C.
As part of the agreement, Kindred will begin installing InMotion robots in its existing inpatient rehabilitation hospitals and similar facilities across the U.S. this month with a second phase to include installation in new Kindred inpatient rehabilitation hospitals and similar facilities within the next four years. "We are thrilled to enter into this agreement with BIONIK and to bring their world-class rehabilitation technology to patients across the country.
The Company intends to use the net proceeds from the offering for working capital, development of technologies or acquisition of new technologies, and/or general corporate purposes. The securities described above will be offered by Bionik Laboratories pursuant to a registration statement on Form S-1 (File No. 333-228044) previously filed with the SEC, but which has not yet become effective. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The reverse stock split has been implemented by the Company on October 29, 2018, in an effort to satisfy the minimum stock price requirement of the Nasdaq Capital Market, for the Company's planned application to list its common stock on Nasdaq. "The completion of the reverse stock split is an integral step in the process of pursuing a successful listing on Nasdaq," said Dr. Eric Dusseux, Chief Executive Officer and Director of Bionik.
The purchase order is for one of BIONIK's improved InMotion Arm™ robotic systems, whose launch was announced this year and recently received a "CE marking" from the European Commission. The CE marking signifies that products sold in the European Economic Area (EEA) have been assessed to meet high safety, health and environmental protection requirements.
With these changes Bionik has seven directors including four independent directors. Dr. Thévenon is a Program Officer on the Board of Life Sciences at The National Academies of Sciences, Engineering and Medicine, where she also serves as the Managing Editor of the journal Institute for Laboratory Animal Research.